These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 3004996)

  • 1. [3H]beta-funaltrexamine binds covalently to brain opioid receptors.
    Tam SW; Nickolson VJ; Liu-Chen LY
    Eur J Pharmacol; 1985 Dec; 119(3):259-60. PubMed ID: 3004996
    [No Abstract]   [Full Text] [Related]  

  • 2. Kinetic studies on binding of [3H] beta-funaltrexamine ([3H] beta-FNA) to mu opioid receptors.
    Liu-Chen LY; Li S; Holowecky O; Tallarida RJ
    Prog Clin Biol Res; 1990; 328():57-60. PubMed ID: 2154818
    [No Abstract]   [Full Text] [Related]  

  • 3. Covalent labeling of mu opioid binding site by [3H]beta-funaltrexamine.
    Liu-Chen LY; Phillips CA
    Mol Pharmacol; 1987 Sep; 32(3):321-9. PubMed ID: 2823089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversible and irreversible binding of beta-funaltrexamine to mu, delta and kappa opioid receptors in guinea pig brain membranes.
    Tam SW; Liu-Chen LY
    J Pharmacol Exp Ther; 1986 Nov; 239(2):351-7. PubMed ID: 3021954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Studies on kinetics of [3H]beta-funaltrexamine binding to mu opioid receptor.
    Liu-Chen LY; Li SX; Tallarida RJ
    Mol Pharmacol; 1990 Feb; 37(2):243-50. PubMed ID: 2154672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beta-[3H]funaltrexamine-labeled mu-opioid receptors: species variations in molecular mass and glycosylation by complex-type, N-linked oligosaccharides.
    Liu-Chen LY; Chen C; Phillips CA
    Mol Pharmacol; 1993 Oct; 44(4):749-56. PubMed ID: 8232225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of intracerebroventricular beta-funaltrexamine on mu and delta opioid receptors in the rat: dichotomy between binding and antinociception.
    Liu-Chen LY; Li SX; Wheeler-Aceto H; Cowan A
    Eur J Pharmacol; 1991 Oct; 203(2):195-202. PubMed ID: 1666046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interaction of beta-funaltrexamine with [3H]cycloFOXY binding in rat brain: further evidence that beta-FNA alkylates the opioid receptor complex.
    Rothman RB; Bykov V; Mahboubi A; Long JB; Jiang Q; Porreca F; de Costa BR; Jacobson AE; Rice KC; Holaday JW
    Synapse; 1991 Jun; 8(2):86-99. PubMed ID: 1652797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [3H] beta-funaltrexamine ([3H] beta-FNA) binds irreversibly to mu opioid receptors in the rat brain: autoradiographic study.
    Liu-Chen LY; Li SX; Rohrbach KW; Lewis ME
    Prog Clin Biol Res; 1990; 328():61-4. PubMed ID: 2154819
    [No Abstract]   [Full Text] [Related]  

  • 10. Autoradiographic study of irreversible binding of [3H]beta-funaltrexamine to opioid receptors in the rat forebrain: comparison with mu and delta receptor distribution.
    Liu-Chen LY; Li SX; Lewis ME
    Brain Res; 1991 Mar; 544(2):235-42. PubMed ID: 1645609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Binding of a new opiate antagonist, nalmefene, to rat brain membranes.
    Michel ME; Bolger G; Weissman BA
    Methods Find Exp Clin Pharmacol; 1985 Apr; 7(4):175-7. PubMed ID: 2991678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of intracerebroventricular beta-funaltrexamine on mu opioid receptors in the rat brain: consideration of binding condition.
    Liu-Chen LY; Yang HH; Li S; Adams JU
    J Pharmacol Exp Ther; 1995 Jun; 273(3):1047-56. PubMed ID: 7791074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. beta-FNA binds irreversibly to the opiate receptor complex: in vivo and in vitro evidence.
    Rothman RB; Long JB; Bykov V; Jacobson AE; Rice KC; Holaday JW
    J Pharmacol Exp Ther; 1988 Nov; 247(2):405-16. PubMed ID: 2846819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Opioid receptor binding characteristics of the non-equilibrium mu antagonist, beta-funaltrexamine (beta-FNA).
    Ward SJ; Fries DS; Larson DL; Portoghese PS; Takemori AE
    Eur J Pharmacol; 1985 Jan; 107(3):323-30. PubMed ID: 2984010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 5-Methylated naloxone, naltrexone, oxymorphone, and their 14-O-methyl ethers.
    Schmidhammer H; Leander JD; Mayer-Valkanover K; Nussbaumer C; Schmidt C; Schoepp DD; Schratz A; Walla-Kugler M
    Prog Clin Biol Res; 1990; 328():41-4. PubMed ID: 2154800
    [No Abstract]   [Full Text] [Related]  

  • 16. Alterations in brain opiate receptors in Parkinson's disease.
    Reisine TD; Rossor M; Spokes E; Iversen LL; Yamamura HI
    Brain Res; 1979 Sep; 173(2):378-82. PubMed ID: 226215
    [No Abstract]   [Full Text] [Related]  

  • 17. Kappa receptor regulation of dopamine release from striatum and cortex of rats and guinea pigs.
    Werling LL; Frattali A; Portoghese PS; Takemori AE; Cox BM
    J Pharmacol Exp Ther; 1988 Jul; 246(1):282-6. PubMed ID: 2839666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of beta-funaltrexamine on radiolabeled opioid binding.
    Recht LD; Pasternak GW
    Eur J Pharmacol; 1987 Aug; 140(2):209-14. PubMed ID: 2822439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Affinity chromatography of solubilized opioid binding sites using CH-Sepharose modified with a new naltrexone derivative.
    Gioannini TL; Howard A; Hiller JM; Simon EJ
    Biochem Biophys Res Commun; 1984 Mar; 119(2):624-9. PubMed ID: 6324770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Molecular aspects of pharmacological activity of naltrexone and naloxone].
    Golovko AI; Golovko SI; Leont'eva LV; Romanenko OI; Konoplin DA
    Eksp Klin Farmakol; 2003; 66(1):71-8. PubMed ID: 12683088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.